Jonathan C. Roberts - 03 Nov 2021 Form 4 Insider Report for CVS HEALTH Corp (CVS)

Role
EVP & Chief Operating Officer
Signature
Jonathan C. Roberts
Issuer symbol
CVS
Transactions as of
03 Nov 2021
Transactions value $
-$5,342,251
Form type
4
Filing time
05 Nov 2021, 16:35:05 UTC
Next filing
28 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CVS Common Stock Options Exercise $5M +109K +101.64% $45.93 216K 03 Nov 2021 Direct
transaction CVS Common Stock Sale -$10.3M -109K -50.41% $95.00 107K 03 Nov 2021 Direct F1
holding CVS Common Stock 34.7K 03 Nov 2021 By GRAT
holding CVS Common Stock (restricted) 12.8K 03 Nov 2021 Direct
holding CVS ESOP Common Stock 6.05K 03 Nov 2021 By ESOP
holding CVS Stock Unit 338K 03 Nov 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CVS Stock Option Options Exercise $0 -109K -100% $0.00* 0 03 Nov 2021 Common Stock 109K $45.93 Direct F2
holding CVS Phantom Stock Credits 1.42K 03 Nov 2021 Common Stock 1.42K $1.00 Direct F3
holding CVS Stock Option 68.5K 03 Nov 2021 Common Stock 68.5K $102.26 Direct F4
holding CVS Stock Option 161K 03 Nov 2021 Common Stock 161K $104.82 Direct F5
holding CVS Stock Option 200K 03 Nov 2021 Common Stock 200K $78.05 Direct F6
holding CVS Stock Option 248K 03 Nov 2021 Common Stock 248K $62.21 Direct F7
holding CVS Stock Option 303K 03 Nov 2021 Common Stock 303K $54.19 Direct F8
holding CVS Stock Option 239K 03 Nov 2021 Common Stock 239K $58.34 Direct F9, F10
holding CVS Stock Option 173K 03 Nov 2021 Common Stock 173K $74.30 Direct F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 All sales were effected pursuant to a Rule 10b5-1 plan.
F2 Option became exercisable in three equal annual installments, commencing 9/4/2015.
F3 Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
F4 Option became exercisable in four equal annual installments, commencing 4/1/2016.
F5 Option became exercisable in four equal annual installments, commencing 4/1/2017.
F6 Option became exercisable in four equal annual installments, commencing 4/3/2018.
F7 Option became exercisable in four equal annual installments, commencing 4/1/2019.
F8 Option became exercisable in four equal annual installments, commencing 4/1/2020.
F9 The number of shares subject to the option were calculated using a 30-day average price.
F10 Options became exercisable in four equal installments, commencing 4/1/2021.
F11 Option becomes exercisable in four equal installments, commencing 4/1/2022.